000			02071na a2200361 4500
999			_c1661 _d1661
003			PC1661
005			20210625062756.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aAntequera, Desiree _92134 _eInstituto de Investigación i+12
100			_aBolos, Marta _92135 _eInstituto de Investigación i+12
100			_aCarro Díaz, Eva _91777 _eInstituto de Investigación i+12
100			_aKrzyzanowska, Agnieszka _92577 _eInstituto de Investigación i+12
100			_aPascual, Consuelo _92349 _eInstituto de Investigación i+12
100			_aPérez González, Rocío _91931 _eInstituto de Investigación i+12
245	0	0	_aPhosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. _h[artículo]
260			_bNeurobiology of aging, _c2013
300			_a34(9):2133-45.
500			_aFormato Vancouver: Pérez-González R, Pascual C, Antequera D, Bolos M, Redondo M, Pérez DI et al. Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013 Sep;34(9):2133-45.
501			_aPMID: 23582662
504			_aContiene 62 referencias
520			_aElevated levels of amyloid beta (Aβ) peptide, hyperphosphorylation of tau protein, and inflammation are pathological hallmarks in Alzheimer's disease (AD). Phosphodiesterase 7 (PDE7) regulates the inflammatory response through the cyclic adenosine monophosphate signaling cascade, and thus plays a central role in AD. The aim of this study was to evaluate the efficacy of an inhibitor of PDE7, named S14, in a mouse model of AD. We report that APP/Ps1 mice treated daily for 4 weeks with S14 show: (1) significant attenuation in behavioral impairment; (2) decreased brain Aβ deposition; (3) enhanced astrocyte-mediated Aβ degradation; and (4) decreased tau phosphorylation. These effects are mediated via the cyclic adenosine monophosphate/cyclic adenosine monophosphate response element-binding protein signaling pathway, and inactivation of glycogen synthase kinase (GSK)3. Our data support the use of PDE7 inhibitors, and specifically S14, as effective therapeutic agents for the prevention and treatment of AD.
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc1661.pdf _ySolicitar documento
942			_n0 _2ddc _cART